Related Experiment Video
Updated: Sep 16, 2025
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
Molecular Markers in the Era of Precision Care in Lung Cancer
Ishan Paranjpe1, Alexander Salter2, Kenneth Chen2
1Department of Medicine, Stanford University School of Medicine, Stanford, California.
Abstract:
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide. The past two decades have brought advances in molecular profiling and the advent of therapies that specifically target genetic and/or molecular alterations in NSCLC. There are now many FDA-approved targeted therapies for patients with metastatic lung cancer who harbor oncogenic driver alterations, including those in epidermal growth factor receptor, ALK receptor tyrosine kinase, KRAS proto-oncogene, GTPase, and others. These advances epitomize personalized medicine and improve patient outcomes compared with conventional cytotoxic chemotherapy. This review highlights the current and evolving landscape of targeted therapies in NSCLC, emphasizing key targets, resistance mechanisms, and new approaches poised to improve patient outcomes in the era of precision oncology. The next decade will likely be marked by further improvements in the specificity, duration of action, and toxicity profiles of targeted therapies, allowing patients to live longer and better lives.
Insights
Targeted therapies offer improved outcomes for non-small cell lung cancer (NSCLC) patients with specific genetic alterations. Future advancements promise enhanced specificity and reduced toxicity for better patient lives.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) remains a significant global health challenge.
- Recent advancements include molecular profiling and targeted therapies for NSCLC.
- Personalized medicine approaches have surpassed traditional chemotherapy in efficacy.
Purpose of the Study:
- To review the current landscape of targeted therapies in NSCLC.
- To highlight key molecular targets and resistance mechanisms.
- To discuss emerging strategies in precision oncology for NSCLC.
Main Methods:
- Literature review of targeted therapies in NSCLC.
- Analysis of FDA-approved targeted agents and their targets.
- Discussion of resistance mechanisms and future therapeutic directions.
Main Results:
- Numerous FDA-approved targeted therapies are available for NSCLC patients with specific oncogenic drivers (e.g., EGFR, ALK, KRAS).
- Targeted therapies demonstrate superior patient outcomes compared to conventional chemotherapy.
- Key targets include EGFR, ALK, and KRAS, with ongoing research into novel alterations.
Conclusions:
- Targeted therapies represent a paradigm shift in NSCLC treatment, embodying personalized medicine.
- Future research will focus on improving specificity, duration, and safety profiles of NSCLC targeted therapies.
- Continued advancements in precision oncology are expected to further enhance survival and quality of life for NSCLC patients.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
